Exosome-Based Ocular Therapeutic

About YD Bio

YD Bio is a diversified biotech company with a multi-platform strategy spanning diagnostics, therapeutics, and clinical trial services. Its core focus is on DNA methylation-based early cancer detection, developed in partnership with EG Biomed, and exosome-based regenerative therapies for ophthalmology, developed with 3D Global Biotech. The company is publicly listed on Nasdaq, leverages strategic partnerships for R&D and commercialization, and operates a revenue-generating clinical trial supply business that supports its development-stage pipeline.

Therapeutic Areas